Among the bevy of programs being established under the current reauthorization of the Prescription Drug User Fee Act (PDUFA VII), the US Food and Drug Administration’s Peter Stein is enthusiastic about a few in particular.
Stein, director of FDA’s Office of New Drugs, spoke about the potential of forthcoming pilot programs at a 14 September session of the Regulatory Affairs Professionals Society’s (RAPS) Convergence meeting